Hypermarcas (HYPMY) Stock Price, News & Analysis

Company Overview

Hypermarcas was a Brazilian consumer-products and pharmaceutical company that later adopted the name Hypera Pharma. The company refocused its operations on pharmaceuticals after divesting a number of businesses in other consumer-goods categories.

Today, Hypera Pharma develops, manufactures and markets medicines in Brazil, including prescription drugs, over-the-counter products and branded generics. Its portfolio also includes vitamins and supplements, and it sells products under brands such as Neo Química and Mantecorp.

The company is based in Brazil and serves the domestic market through its pharmaceutical operations. Its evolution from a diversified consumer-products group into a pharmaceutical-focused business is an important part of Hypermarcas’ corporate history.

Key Stats

• Today's Range: $3.94 to $4.02
• 50-Day Range: $3.83 to $5.40
• 52-Week Range: $3.39 to $5.77
• Volume: 13,827 shs
• Average Volume: 45,846 shs
• Market Capitalization: $2.77 billion
• P/E Ratio: 7.58
• Dividend Yield: 3.30%
• Price Target: N/A
• Consensus Rating: Buy

Hypermarcas Stock Analysis - MarketRank™

Hypermarcas scored higher than 67% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.5 / 5
• Analyst Rating: Buy

Consensus Rating

Hypermarcas has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 strong buy rating, no buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Hypermarcas has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 3.1 / 5
• Proj. Earnings Growth: 16.00%

Earnings Growth

Earnings for Hypermarcas are expected to grow by 16.00% in the coming year, from $0.50 to $0.58 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Hypermarcas is 7.58, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 25.41.

Price to Earnings Ratio vs. Sector

The P/E ratio of Hypermarcas is 7.58, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 34.71.

Price to Book Value per Share Ratio

Hypermarcas has a P/B Ratio of 1.11. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.00% of the float of Hypermarcas has been sold short.

Short Interest Ratio / Days to Cover

Hypermarcas has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Hypermarcas has recently increased by 390.03%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 2.5 / 5
• Dividend Strength: Moderate

Dividend Yield

Hypermarcas pays a meaningful dividend of 3.18%, higher than the bottom 25% of all stocks that pay dividends.

Dividend Growth

Hypermarcas does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Hypermarcas is 26.00%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, Hypermarcas will have a dividend payout ratio of 22.41% next year. This indicates that Hypermarcas will be able to sustain or increase its dividend.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.50

News Sentiment

Hypermarcas has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Hypermarcas this week, compared to 0 articles on an average week.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Hypermarcas insiders have not sold or bought any company stock.

Percentage Held by Institutions

Hypermarcas has minimal institutional ownership at this time.

Company Calendar

• Ex-Dividend for 1/8 Dividend: 6/30/2025
• Record date for 1/8 Dividend: 7/01/2025
• Last Earnings: 11/11/2026
• Today: 11/14/2026
• Fiscal Year End: 12/31/2026
• Dividend Payable: 1/08/2027

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: OTCMKTS:HYPMY
• CIK: 1486749
• Web: www.hypera.com.br
• Phone: 55-11-3627-4206
• Fax: N/A
• Employees: 10,564
• Year Founded: 2001

Profitability

• EPS (Trailing Twelve Months): $0.50
• Trailing P/E Ratio: 7.58
• Forward P/E Ratio: 6.79
• P/E Growth: N/A
• Net Income: $213.10 million
• Net Margins: 20.07%
• Pretax Margin: N/A
• Return on Equity: 12.58%
• Return on Assets: 7.00%

Debt

• Debt-to-Equity Ratio: 0.50
• Current Ratio: 1.86
• Quick Ratio: 1.26

Sales & Book Value

• Annual Sales: $1.38 billion
• Price / Sales: 2.01
• Cash Flow: $0.47 per share
• Price / Cash Flow: 8.42
• Book Value: $3.54 per share
• Price / Book: 1.11

Miscellaneous

• Outstanding Shares: 704,010,000
• Free Float: N/A
• Market Cap: $2.77 billion
• Optionable: Not Optionable
• Beta: 0.78